Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Allopurinol

FDA-approved product (tablet, oral), marketed as Allopurinol, Lopurin, Zyloprim and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Allopurinol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gout
  • Leukemia
  • Lymphoma
  • Response Evaluation Criteria in Solid Tumors

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations inhibiting uric acid production
FDA pharmacologic class
Xanthine Oxidase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Allopurinol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis2.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Allopurinol in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Allopurinol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

    NCT01265264 · start 2010-12

    Registered record
    Registry ID
    NCT01265264
    Conditions
    Gout; Hyperuricemia; Arthritis; Joint Disease
    Interventions
    ulodesine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2013-02
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Hyperuricemia; Arthritis; Joint Disease
    Interventionulodesine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Hyperuricemia on Hypertension and Metabolic Syndrome

    NCT01157936 · start 2010-07

    Registered record
    Registry ID
    NCT01157936
    Conditions
    Systolic and Diastolic Blood Pressure Levels; Uric Acid Levels; Metabolic Syndrome Parameters; Hepatic Enzymes
    Interventions
    Allopurinol; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystolic and Diastolic Blood Pressure Levels; Uric Acid Levels; Metabolic Syndrome Parameters; Hepatic Enzymes
    InterventionAllopurinol; placebo
    PhasePhase 2
    Registry statusCompleted

  • Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

    NCT01109121 · start 2010-06

    Registered record
    Registry ID
    NCT01109121
    Conditions
    Moderate to Severe Gout; Hyperuricemia
    Interventions
    Combination 400; Allopurinol; Combination 600
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-01
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Gout; Hyperuricemia
    InterventionCombination 400; Allopurinol; Combination 600
    PhasePhase 2
    Registry statusCompleted

  • Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

    NCT01101035 · start 2010-04-23

    Registered record
    Registry ID
    NCT01101035
    Conditions
    Cardiovascular Disease
    Interventions
    Febuxostat; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04-23
    Completion
    2017-07-18
    Enrolment
    6,198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionFebuxostat; Allopurinol
    PhasePhase 3
    Registry statusCompleted

  • Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

    NCT01077284 · start 2010-02

    Registered record
    Registry ID
    NCT01077284
    Conditions
    Hyperuricosuria; Kidney Stones
    Interventions
    Febuxostat; Allopurinol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02
    Completion
    2011-11
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperuricosuria; Kidney Stones
    InterventionFebuxostat; Allopurinol; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

    NCT01052987 · start 2010-01

    Registered record
    Registry ID
    NCT01052987
    Conditions
    Gout; Hyperuricemia
    Interventions
    Tranilast; Allopurinol; Combination - Tranilast and Allopurinol; 400 mg Allopurinol; High dose combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Hyperuricemia
    InterventionTranilast; Allopurinol; Combination - Tranilast and Allopurinol; 400 mg Allopurinol +1 more
    PhasePhase 2
    Registry statusCompleted

  • Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    NCT00940524 · start 2009-07

    Registered record
    Registry ID
    NCT00940524
    Conditions
    Leukemia; Acute Lymphoblastic Leukemia
    Interventions
    Dasatinib, Mitoxantrone, Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07
    Completion
    2014-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Acute Lymphoblastic Leukemia
    InterventionDasatinib, Mitoxantrone, Cytarabine
    PhasePhase 1
    Registry statusCompleted

  • PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

    NCT00958438 · start 2009-07

    Registered record
    Registry ID
    NCT00958438
    Conditions
    Gout
    Interventions
    Placebo; Rilonacept; Rilonacept
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-12
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionPlacebo; Rilonacept; Rilonacept
    PhasePhase 3
    Registry statusCompleted

  • Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

    NCT00899431 · start 2009-05-06

    Registered record
    Registry ID
    NCT00899431
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Lenalidomide; Fludarabine; Rituximab; Thymoglobulin; Stem Cell Transplantation; Bendamustine; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-05-06
    Completion
    2018-10-07
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionLenalidomide; Fludarabine; Rituximab; Thymoglobulin +3 more
    PhasePhase 2
    Registry statusTerminated

  • Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

    NCT00856206 · start 2009-03

    Registered record
    Registry ID
    NCT00856206
    Conditions
    Gout
    Interventions
    Rilonacept; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-01
    Enrolment
    1,315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionRilonacept; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

    NCT00819585 · start 2008-12

    Registered record
    Registry ID
    NCT00819585
    Conditions
    Gout
    Interventions
    Canakinumab; Colchicine; Allopurinol; Placebo Matching Canakinumab; Placebo Matching Colchicine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-08
    Enrolment
    432

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionCanakinumab; Colchicine; Allopurinol; Placebo Matching Canakinumab +1 more
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol

    NCT00480883 · start 2008-01

    Registered record
    Registry ID
    NCT00480883
    Conditions
    Leishmaniasis, Cutaneous
    Interventions
    meglumine antimoniate, allopurinol; meglumine antimoniate; meglumine antimoniate, allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous
    Interventionmeglumine antimoniate, allopurinol; meglumine antimoniate; meglumine antimoniate, allopurinol
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

    NCT01603134 · start 2007-11

    Registered record
    Registry ID
    NCT01603134
    Conditions
    Fasting State
    Interventions
    Allopurinol; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11
    Completion
    2008-04
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasting State
    InterventionAllopurinol; Allopurinol
    PhasePhase 1
    Registry statusCompleted

  • T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

    NCT00602693 · start 2007-07-23

    Registered record
    Registry ID
    NCT00602693
    Conditions
    Leukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm; Myelodysplastic Syndromes
    Interventions
    umbilical cord blood transplantation; Allopurinol; fludarabine phosphate; Cyclophosphamide; Total body irradiation; Treg infusion; Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-07-23
    Completion
    2015-04-16
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm +1 more
    Interventionumbilical cord blood transplantation; Allopurinol; fludarabine phosphate; Cyclophosphamide +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

    NCT00401388 · start 2006-11

    Registered record
    Registry ID
    NCT00401388
    Conditions
    Chondrosarcomas; Alveolar Soft Part Sarcomas; Extra Skeletal Myxoid Chondrosarcomas
    Interventions
    Perifosine; Loperamide; Allopurinol; Antiemetics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-11
    Completion
    2011-10
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChondrosarcomas; Alveolar Soft Part Sarcomas; Extra Skeletal Myxoid Chondrosarcomas
    InterventionPerifosine; Loperamide; Allopurinol; Antiemetics
    PhasePhase 2
    Registry statusCompleted